Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster presentation 1

1231 - The retrospective analysis of gemcitabine + nab-paclitaxel in advanced pancreatic cancer


19 Dec 2015


Poster presentation 1


Makoto Ueno


Annals of Oncology (2015) 26 (suppl_9): 42-70. 10.1093/annonc/mdv523


M. Ueno1, S. Kobayashi2, S. Ohkawa2, S. Tezuka2, S. Moriya2, M. Morimoto2

Author affiliations

  • 1 Division Of Hepatobiliary And Pancreatic Medical Oncology, Kanagawa Cancer Center, 241-8515 - Yokohama/JP
  • 2 Division Of Hepatobiliary And Pancreatic Medical Oncology, Kanagawa Cancer Center, Yokohama/JP


Abstract 1231


Gemcitabine + nab-paclitaxel is one of the standard chemotherapies to treat advanced pancreatic cancer (APC). MPACT trial included a small number of Asian patients. In Japan, gemcitabine + nab-paclitaxel was approved for clinical use in December 2014. We performed gemcitabine + nab-paclitaxel in various lines in practice. Here, we examined the results of this treatment retrospectively in APC patients.


The subjects were 92 APC patients. They were treated with gemcitabine + nab-paclitaxel starting from Dec. 2014 to July 2015. Both gemcitabine (1000 mg/m2) and nab-paclitaxel (125 mg/m2) were administered on days 1, 8, and 15 for every 4 weeks. UICC stage, sex, age, performance status, febrile neutropenia, and antitumor effect based on RECIST criteria (v1.1) were examined.


UICC stages were as follows; stage III: 17, stage IV: 60, and recurrence: 15. There were 54 males and 38 females, and their ages ranged from 44 to 83 years old (median: 67). The performance status was as follows; 0: 41, 1: 48, 2: 3. The treatment line was as follows; 1st: 57, 2nd: 15, 3rd: 15, 4th: 5. The febrile neutropenia was seen in only 2 patients (2%). The disease control rate (DCR) (PR + SD) was follows; 1st: 81%, remaining line: 80%. The DCR was 63% in gemcitabine refractory patients.


Gemcitabine + nab-paclitaxel was effective as a 1st line chemotherapy as well as other lines to treat APC in practice.

Clinical trial identification


M. Ueno: honoraria Abbott, Eli Lilly, Taiho Yakult and AstraZeneca Research Funding Taiho, Daiichi-Sankyo, Zeria, Merck Serono. S. Kobayashi: honoraria Taiho Yakult and AstraZeneca. M. Morimoto: honoraria: Bayer, Dainippon-Sumitomo, Eisai, Nippon-Kayaku Resarch Funding: Bayer, Yakult, Shionogi, Eli Lilly, Kowa, Kyowa-Hakko-Kirin. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings